P87 - Main mechanisms of pharmacokinetic drug-drug interactions triggering label recommendations for drugs approved by the food and drug administration in 2018

2020 ◽  
Vol 35 (1) ◽  
pp. S49
Author(s):  
Jingjing Yu ◽  
Ichiko Petrie ◽  
Isabelle Ragueneau-Majlessi
Keyword(s):  
Drug Interactions ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Pharmacokinetic Drug

Saphris: Does a unique delivery system equal a unique drug?

2011 ◽  
Vol 1 (6) ◽  
pp. 133-134
Author(s):  
Kelly N. Gable
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Delivery System ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

scholarly journals Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016

2018 ◽  
Vol 46 (6) ◽  
pp. 835-845 ◽  
Author(s):  
Jingjing Yu ◽  
Zhu Zhou ◽  
Jessica Tay-Sontheimer ◽  
René H. Levy ◽  
Isabelle Ragueneau-Majlessi
Keyword(s):  
Drug Interactions ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
The U.S

scholarly journals Viibryd (Vilazodone): Viable option or for the byrds?

2011 ◽  
Vol 1 (6) ◽  
pp. 140-141
Author(s):  
Misty L. Gonzalez
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
Viable Option ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Vilazodone was approved by the Food and Drug Administration (FDA) in January of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Iloperidone (Fanapt®): Fan or not?

2011 ◽  
Vol 1 (6) ◽  
pp. 137-139
Author(s):  
Uma Newton ◽  
Tiffany-Jade Kreys
Keyword(s):  
Clinical Trial ◽  
Adverse Effects ◽  
Drug Interactions ◽  
Drug Administration ◽  
Mechanism Of Action ◽  
Food And Drug Administration ◽  
New Drug ◽  
Clinical Trial Evidence ◽  
Clinically Significant ◽  
Trial Evidence

Iloperidone was approved by the Food and Drug Administration (FDA) in May of 2009. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.

Sign in / Sign up

Export Citation Format

Share Document